QGEN vs. SNY: Qiagen vs. Sanofi Stock Comparison

Company Profile

Qiagen (QGEN) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but QGEN is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.

Qiagen (QGEN) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Qiagen (QGEN) at 10.81% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for QGEN.

Qiagen (QGEN) at 18.20% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

Both Qiagen (QGEN) at 27.75% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Qiagen (QGEN) at 5.65% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Qiagen (QGEN) at 409.76% clears its industry range for EPS growth, a much stronger earnings trajectory than Sanofi (SNY) at 39.43%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Both Qiagen (QGEN) at 0.47 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Qiagen (QGEN) reports 18.21%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Qiagen (QGEN) at 27.21 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Qiagen (QGEN) at 4.91 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Qiagen (QGEN) at 2.99 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics